Novo Nordisk pens $2B deal for triple G agonist tied to 15% weight loss at 12 weeks

Novo Nordisk’s attempt to create a successor to its weight loss blockbuster Wegovy may have taken a hit with recent underwhelming data for CagriSema, but the Danish pharma has given itself another option thanks to a $2 billion deal with China’s United Laboratories.